共 95 条
[1]
Kobayashi Y(2020)Management of ovarian cancer patients in affected areas during COVID-19 pandemic: Japan and Korea J Gynecol Oncol 31 1732-1742
[2]
Suh DH(1993)Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis J Natl Cancer Inst 85 532-535
[3]
Aoki D(2011)Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer Gynecol Oncol 122 74-80
[4]
Kim JW(2013)Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer Gynecol Oncol 129 1383-1393
[5]
Levin L(2015)Dose delays, dose reductions, and relative dose intensity in patients with Cancer who received adjuvant or Neoadjuvant chemotherapy in community oncology practices J Natl Compr Canc Netw 13 380-386
[6]
Simon R(2018)Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian Cancer Clin Breast Cancer 18 925-932
[7]
Hryniuk W(2020)Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer Support Care Cancer 28 30674-30678
[8]
Fauci JM(2020)Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer Am J Obstetrics Gynecol S0002–9378 862-864
[9]
Whitworth JM(2020)Poor clinical outcomes for patients with cancer during the COVID-19 pandemic Lancet Oncol 21 894-901
[10]
Schneider KE(2020)Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Ann Oncol 31 3624-3627